EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders

Ping Hu, Kaiqi Li, Xiaoxu Peng, Yufei Kan, Hao Li, Yanli Zhu iD, Ziyu Wang, Zhaojian Li, Hao-Yu Liu, Demin Cai iD

Nutrients · 13.11.2023 · 15 (22) · 4772

DOI: 10.3390/nu15224772 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 13.11.2023. Verfasst von Ping Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China. Hauptthemen laut MEDLINE: Lipid Metabolism Disorders, Metabolic Diseases. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lipid metabolic diseases have substantial morbidity and mortality rates, posing a significant threat to human health. PPARα, a member of the peroxisome proliferator-activated receptors (PPARs), plays a crucial role in lipid metabolism and immune regulation. Recent studies have increasingly recognized the pivotal involvement of PPARα in diverse pathological conditions. This comprehensive review aims to elucidate the multifaceted role of PPARα in metabolic diseases including liver diseases, diabetes-related diseases, age-related diseases, and cancers, shedding light on the underlying molecular mechanisms and some regulatory effects of natural/synthetic ligands of PPARα. By summarizing the latest research findings on PPARα, we aim to provide a foundation for the possible therapeutic exploitation of PPARα in lipid metabolic diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipid Metabolism DisordersMetabolic DiseasesHumansPPAR alphaLipid MetabolismReceptors, Cytoplasmic and NuclearLipids

Stichwörter der Autor:innen

PPARαcancercell senescencediabetes-related diseaseslipid metabolismmetabolic disorders

Substanzen

PPAR alphaReceptors, Cytoplasmic and NuclearLipids

Autor:innen und Institutionen

  • College of Animal Science and Technology, Yangzhou University, Yangzhou 225009, China.
  • International Joint Research Laboratory in Universities of Jiangsu Province of China for Domestic Animal Germplasm Resources and Genetic Improvement, Yangzhou 225009, China.

ORCID-Profile: Yanli Zhu, Demin Cai

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Jiangsu Province
  • Jiangsu Funding Program for Excellent Postdoctoral Talent
  • Open Project Program of International Joint Research Laboratory in Universities of Jiangsu Province of China for Domestic Animal Germplasm Resources and Geneti…

Zitieren

APA

Hu, P., Li, K., Peng, X., Kan, Y., Li, H., Zhu, Y., Wang, Z., Li, Z., Liu, H. Y., & Cai, D. (2023). Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders. Nutrients, 15(22), 4772. https://doi.org/10.3390/nu15224772

Vancouver

Hu P, Li K, Peng X, Kan Y, Li H, Zhu Y, et al. Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders. Nutrients. 2023;15(22):4772. doi:10.3390/nu15224772

BibTeX
@article{Hu2023,
  author = {Hu, Ping and Li, Kaiqi and Peng, Xiaoxu and Kan, Yufei and Li, Hao and Zhu, Yanli and Wang, Ziyu and Li, Zhaojian and Liu, Hao-Yu and Cai, Demin},
  title = {Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders},
  journal = {Nutrients},
  year = {2023},
  volume = {15},
  number = {22},
  pages = {4772},
  doi = {10.3390/nu15224772}
}
Kostenlos starten →